EX-10.1




 Exhibit 10.1  

SECURITIES PURCHASE AGREEMENT 

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of December 5, 2022 by and among Karyopharm
Therapeutics Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). 

RECITALS 

A.    The Company and the Investors are executing and delivering this Agreement in reliance upon the exemption from
securities registration afforded by the provisions of Section 4(a)(2) of the 1933 Act (as defined below), and Rule 506 of Regulation D (“Regulation D”) as promulgated by the SEC (as defined below) under the 1933 Act; 

B.    The Investors wish to purchase from the Company, and the Company wishes to sell and issue to the Investors, upon the
terms and subject to the conditions stated in this Agreement, (i) an aggregate of 31,791,908 shares (the “Shares”) of the Company’s Common Stock, par value $0.0001 per share (the “Common Stock”) and
(ii) warrants to purchase an aggregate of 9,537,563 shares of the Company’s Common Stock in the form attached hereto as Exhibit B (each, a “Warrant” and collectively, the “Warrants; and 

C.    Contemporaneously with the sale of the Shares and the Warrants, the parties hereto will execute and deliver a
Registration Rights Agreement, in the form attached hereto as Exhibit C (the “Registration Rights Agreement”), pursuant to which the Company will agree to provide certain registration rights in respect of
the Shares and the Warrant Shares (as defined below) under the 1933 Act and applicable state securities laws. 
 In consideration of the
mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows: 

1.    Definitions. For the purposes of this Agreement, the following terms shall have the meanings set forth below:

 “Additional Disclosure” means the presentation referred to in Section 4.28 of the Disclosure Schedule. 

“Affiliate” means, with respect to any Person, any other Person which directly or indirectly through one or more
intermediaries Controls, is controlled by, or is under common Control with such Person. 
 “Business Day” means a day,
other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business. 
 “Cleansing
Disclosure” has the meaning set forth in Section 9.7(c). 
 “Closing” has the meaning set forth in
Section 3.1. 











 “Closing Date” has the meaning set forth in Section 3.1. 

“Common Stock” has the meaning set forth in the recitals to this Agreement. 

“Common Stock Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time
Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. 

“Company Covered Person” means, with respect to the Company as an “issuer” for purposes of Rule 506 promulgated
under the 1933 Act, any Person listed in the first paragraph of Rule 506(d)(1). 
 “Company’s Knowledge” means the
actual knowledge of the executive officers (as defined in Rule 405 under the 1933 Act) of the Company. 
 “Control”
(including the terms “controlling,” “controlled by” or “under common control with”) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person,
whether through the ownership of voting securities, by contract or otherwise. 
 “Disqualification Event” has the meaning
set forth in Section 4.34. 
 “EDGAR system” has the meaning set forth in Section 4.9. 

“Effective Date” has the meaning set forth in Section 7.2(b). 

“Environmental Laws” has the meaning set forth in Section 4.15. 

“GAAP” has the meaning set forth in Section 4.17. 

“Intellectual Property” has the meaning set forth in Section 4.14. 

“Material Adverse Effect” means a material adverse effect on (i) the assets, liabilities, results of operations,
financial condition or business of the Company and its subsidiaries taken as a whole, (ii) the legality or enforceability of any of the Transaction Documents or (iii) the ability of the Company to perform its obligations under the
Transaction Documents, except that for purposes of Section 6.1(i) of this Agreement, in no event shall a change in the market price of the Common Stock alone constitute a “Material Adverse Effect”. 

“Material Contract” means any contract, instrument or other agreement to which the Company is a party or by which it is bound
that has been filed or was required to have been filed as an exhibit to the SEC Filings pursuant to Item 601(b)(4) or Item 601(b)(10) of Regulation S-K. 

“Nasdaq” means the Nasdaq Global Select Market. 

  
 2 












 “Person” means an individual, corporation, partnership, limited liability
company, trust, business trust, association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein. 

“Placement Agents” means Jefferies LLC, Piper Sandler & Co. Barclays Capital, Inc., Robert W. Baird & Co.
Incorporated and H.C. Wainwright & Co., LLC. 
 “Placement Securities” means the Shares and the Warrants. 

“Press Release” has the meaning set forth in Section 9.7(b). 

“Principal Trading Market” means the Trading Market on which the Common Stock is primarily listed on and quoted for trading,
which, as of the date of this Agreement and the Closing Date, shall be the Nasdaq Global Select Market. 
 “Registration Rights
Agreement” has the meaning set forth in the recitals to this Agreement. 
 “Regulation D” has the meaning set
forth in the recitals to this Agreement. 
 “Required Investors” has the meaning set forth in the Registration Rights
Agreement. 
 “SEC” means the U.S. Securities and Exchange Commission. 

“SEC Filings” has the meaning set forth in Section 4.8. 

“Securities” means the Placement Securities and the Warrant Shares. 

“Shares” has the meaning set forth in the recitals to this Agreement. 

“Short Sales” means all “short sales” as defined in Rule 200 of Regulation SHO under the 1934 Act (but shall not be
deemed to include the location and/or reservation of borrowable shares of Common Stock). 
 “Trading Day” means (i) a
day on which the Common Stock is listed or quoted and traded on its Principal Trading Market or (ii) if the Common Stock is not quoted on any Trading Market, a day on which the Common Stock is quoted in the over-the-counter market as reported in the “pink sheets” by OTC Markets Group Inc. (or any similar organization or agency succeeding to its functions of reporting prices); provided, that in the
event that the Common Stock is not listed or quoted as set forth in (i) or (ii) hereof, then Trading Day shall mean a Business Day. 

“Trading Market” means whichever of the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the
Nasdaq Global Market, the Nasdaq Capital Market on which the Common Stock is listed or quoted for trading on the date in question. 

“Transfer Agent” has the meaning set forth in Section 7.2(a). 

“Transaction Documents” means this Agreement, the Registration Rights Agreement and the Warrants. 

  
 3 












 “Warrant Shares” means the shares of Common Stock issuable upon exercise of
the Warrants. 
 “Warrants” has the meaning set forth in the recitals to this Agreement. 

“1933 Act” means the Securities Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated
thereunder. 
 “1934 Act” means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules
and regulations promulgated thereunder. 
 2.    Purchase and Sale of the Placement Securities. On the Closing
Date, upon the terms and subject to the conditions set forth herein, the Company will issue and sell, and each Investors will purchase, severally and not jointly, (A) the number of Shares set forth opposite the name of such Investor under the
heading “Number of Shares to be Purchased” on Exhibit A attached hereto and (B) a Warrant to purchase the number of Warrant Shares set forth opposite the name of such Investor under the heading “Number of Warrant Shares
Underlying Warrant Purchased” on Exhibit A attached hereto. The Shares will be sold in fixed combinations with the Warrants, with each Investor receiving a Warrant to purchase three shares of Common Stock per every 10 Shares purchased by
such Investor. The purchase price per Share and accompanying Warrant shall be $5.19. The Warrants shall have an exercise price equal to $6.3578 per Warrant Share. 

3.    Closing. 

3.1.    Upon the satisfaction or waiver of the conditions set forth in Section 6, the completion
of the purchase and sale of the Placement Securities (the “Closing”) shall occur remotely via exchange of documents and signatures at a time (the “Closing Date”) to be agreed to by the Company and the Investors but
(i) in no event earlier than the second Business Day after the date hereof and (ii) in no event later than the fifth Trading Day after the date hereof, and of which the Investors will be notified in advance by the Placement Agents. 

3.2.    On or before the Closing Date, each Investor shall deliver or cause to be delivered to the Company, via wire
transfer of immediately available funds pursuant to the wire instructions delivered to such Investor by the Company on or prior to the Closing Date, an amount equal to the purchase price to be paid by the Investor for the Placement Securities to be
acquired by it as set forth opposite the name of such Investor under the heading “Aggregate Purchase Price of Placement Securities” on Exhibit A attached hereto. If the Closing has not occurred for any reason on or prior to the
fifth Trading Date after the date hereof and the Agreement has been terminated by the Investor pursuant to Section 6.3, the applicable purchase price shall be promptly returned to the applicable Investor. 

3.3.    At or before the Closing, the Company shall deliver or cause to be delivered to each Investor (A) a number of
Shares, registered in the name of the Investor (or its nominee in accordance with its delivery instructions), equal to the number of Shares set forth opposite the name of such Investor under the heading “Number of Shares to be Purchased”
on Exhibit A attached hereto and (B) a Warrant, registered in the name of the Investor (or its nominee in accordance with its delivery instructions), to purchase up to the number of Warrant


  
 4 












 
Shares set forth opposite the name of such Investor under the heading “Number of Warrant Shares Underlying Warrant Purchased” on Exhibit A attached hereto. The Shares shall be
delivered via a book-entry record through the Company’s transfer agent. Unless the Company and an Investor otherwise mutually agree with respect to such Investor’s Shares, at Closing settlement shall occur on a “delivery versus
payment” basis. 
 4.    Representations and Warranties of the Company. The Company hereby represents and
warrants to the Investors that, except as set forth on the disclosure schedule delivered herewith (which is arranged in numbered and lettered sections corresponding to the numbered and lettered sections contained in this Section 4) (the
“Disclosure Schedule”), each of which qualify these representations and warranties in their entirety: 

4.1.    Organization, Good Standing and Qualification. The Company is a corporation duly organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to carry on its business as now conducted and to own or lease its properties. The Company is duly qualified to
do business as a foreign corporation and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property makes such qualification or leasing necessary unless the failure to so qualify has not had
and would not reasonably be expected to have a Material Adverse Effect. The Company’s subsidiaries are set forth on Exhibit 21.1 to its most recent Annual Report on Form 10-K, and the Company owns 100% of
the outstanding equity securities of such subsidiaries. The Company’s subsidiaries are duly organized, validly existing and in good standing under the laws of their jurisdiction of organization and have all requisite power and authority to
carry on their business as now conducted and to own or lease their properties. The Company’s subsidiaries are duly qualified to do business as foreign corporations and are in good standing in each jurisdiction in which the conduct of their
business or their ownership or leasing of property makes such qualification or leasing necessary unless the failure to so qualify has not had and would not reasonably be expected to have a Material Adverse Effect. 

4.2.    Authorization. The Company has the requisite corporate power and authority and has taken all requisite
corporate action necessary for, and no further action or consent of the Company, its officers, directors and stockholders is necessary for, (i) the authorization, execution and delivery of the Transaction Documents, (ii) the authorization
of the performance of all obligations of the Company hereunder or thereunder, and (iii) the authorization, issuance (or reservation for issuance) and delivery of the Securities. The Transaction Documents constitute the legal, valid and binding
obligations of the Company, enforceable against the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting
creditors’ rights generally and to general principles of equity. 
 4.3.    Capitalization. The Company is
authorized under its Certificate of Incorporation to issue 200,000,000 shares of Common Stock. The Company’s disclosure of its issued and outstanding capital stock in its most recent SEC Filing containing such disclosure was accurate in all
material respects as of the date indicated in such SEC Filing. All of the issued and outstanding shares of the Company’s capital stock have been duly authorized and validly issued 

  
 5 












 
and are fully paid and nonassessable; none of such shares were issued in violation of any preemptive rights; and such shares were issued in compliance in all material respects with applicable
state and federal securities law and any rights of third parties. No Person is entitled to preemptive or similar statutory or contractual rights with respect to the issuance by the Company of any securities of the Company, including, without
limitation, the Placement Securities. Except for the 3.00% convertible senior notes due 2025 and stock options and restricted stock units granted under Company stock-based compensation plans that are described in the SEC Filings, there are no
outstanding warrants, options, convertible securities or other rights, agreements or arrangements of any character under which the Company is or may be obligated to issue any equity securities of any kind, except as contemplated by this Agreement or
as previously disclosed in the Company’s SEC Filings. There are no voting agreements, buy-sell agreements, option or right of first purchase agreements or other similar agreements among the Company and
any of the securityholders of the Company relating to the securities of the Company held by them. No Person has the right to require the Company to register any securities of the Company under the 1933 Act, whether on a demand basis or in connection
with the registration of securities of the Company for its own account or for the account of any other Person. 
 The issuance and sale of
the Securities hereunder will not obligate the Company to issue shares of Common Stock or other securities to any other Person (other than the Investors) and will not result in the adjustment of the exercise, conversion, exchange or reset price of
any outstanding security. 
 The Company does not have outstanding stockholder purchase rights or “poison pill” or any similar
arrangement in effect giving any Person the right to purchase any equity interest in the Company upon the occurrence of certain events. 

4.4.    Valid Issuance. The Shares have been duly and validly authorized and, when issued and paid for pursuant to
this Agreement, will be validly issued, fully paid and nonassessable, and shall be free and clear of all encumbrances and restrictions (other than those created by any Investor with respect to Shares purchased by such Investor), except for
restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws. The Warrant Shares have been duly and validly authorized and reserved for issuance and, upon exercise of the Warrants in accordance with their
terms, including the payment of any exercise price therefor, will be validly issued, fully paid and nonassessable and will be free and clear of all encumbrances and restrictions (other than those created by any Investor with respect to Warrant
Shares purchased by such Investor), except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws. 

4.5.    Consents. Subject to the accuracy of the representations and warranties of each Investor set forth in
Section 5 hereof, the execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance and sale of the Placement Securities require no consent of, action by or in respect of, or filing with, any Person,
governmental body, agency, or official other than (a) filings that have been made pursuant to applicable state securities laws, (b) post-sale filings pursuant to applicable state and federal securities laws, (c) filings pursuant to
the rules and regulations of Nasdaq and (d) filing of the registration statement required to be filed by the Registration Rights Agreement, each of which 

  
 6 












 
the Company has filed or undertakes to file within the applicable time. Subject to the accuracy of the representations and warranties of each Investor set forth in Section 5 hereof, the
Company has taken all action necessary to exempt (i) the issuance and sale of the Securities and (ii) the other transactions contemplated by the Transaction Documents from the provisions of any anti-takeover, business combination or
control share law or statute binding on the Company or to which the Company or any of its assets and properties is subject that is or could reasonably be expected to become applicable to the Investors as a result of the transactions contemplated
hereby, including without limitation, the issuance of the Securities and the ownership, disposition or voting of the Shares or the Warrant Shares by the Investors or the exercise of any right granted to the Investors pursuant to this Agreement or
the other Transaction Documents. 
 4.6.    Use of Proceeds. The net proceeds of the sale of the Placement
Securities hereunder shall be used by the Company for working capital and general corporate purposes. 
 4.7.    No
Material Adverse Change. Since September 30, 2022 there has not been: 
 (i)    any change in the consolidated
assets, liabilities, financial condition or operating results of the Company from that reflected in the financial statements included in the Company’s Quarterly Report on Form 10-Q for the quarter ended
September 30, 2022, except for changes in the ordinary course of business which have not had and would not reasonably be expected to have a Material Adverse Effect, individually or in the aggregate; 

(ii)    any declaration or payment by the Company of any dividend, or any authorization or payment by the Company of any
distribution, on any of the capital stock of the Company, or any redemption or repurchase by the Company of any securities of the Company; 

(iii)    any material damage, destruction or loss, whether or not covered by insurance, to any assets or properties of
the Company; 
 (iv)    any waiver, not in the ordinary course of business, by the Company of a material right or of a
material debt owed to it; 
 (v)    any satisfaction or discharge of any lien, claim or encumbrance or payment of any
obligation by the Company, except in the ordinary course of business and which is not material to the assets, properties, financial condition, operating results or business of the Company (as such business is presently conducted); 

(vi)    any change or amendment to the Company’s Certificate of Incorporation or Bylaws, or material change to any
material contract or arrangement by which the Company is bound or to which any of its assets or properties is subject; 

(vii)    any material labor difficulties or, to the Company’s Knowledge, labor union organizing activities with
respect to employees of the Company; 
 (viii)    any material transaction entered into by the Company other than in
the ordinary course of business; 

  
 7 












 (ix)    the loss of the services of any executive officer (as defined
in Rule 405 under the 1933 Act); or 
 (x)    any other event or condition that has had or would reasonably be expected
to have a Material Adverse Effect. 
 4.8.    SEC Filings. The Company has filed all reports, schedules, forms,
statements and other documents required to be filed by the Company under the 1933 Act and the 1934 Act, including pursuant to Section 13(a) or 15(d) thereof, for the one-year period preceding the date
hereof (collectively, the “SEC Filings”). The Company meets the requirements for use of Form S-3 under the 1933 Act. At the time of filing thereof, the SEC Filings complied as to form in all
material respects with the requirements of the 1933 Act or the 1934 Act, as applicable, and the rules and regulations of the SEC thereunder. 

4.9.    No Conflict, Breach, Violation or Default. The execution, delivery and performance of the Transaction
Documents by the Company and the issuance and sale of the Placement Securities in accordance with the provisions thereof will not, except (solely in the case of clauses (i)(b) and (ii)) for such violations, conflicts or defaults as would not
reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, (i) conflict with or result in a breach or violation of (a) any of the terms and provisions of, or constitute a default under, the Company’s
Certificate of Incorporation or the Company’s Bylaws, both as in effect on the date hereof (true and complete copies of which have been made available to the Investors through the Electronic Data Gathering, Analysis, and Retrieval system (the
“EDGAR system”)), or (b) assuming the accuracy of the representations and warranties in Section 5, any applicable statute, rule, regulation or order of any governmental agency or body or any court, domestic or foreign,
having jurisdiction over the Company or its subsidiaries, or any of their assets or properties, or (ii) conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in the
creation of any lien, encumbrance or other adverse claim upon any of the properties or assets of the Company or its subsidiaries or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of
time or both) of, any Material Contract. This Section does not relate to matters with respect to tax status, which are the subject of Section 4.10, employee relations and labor matters, which are the subject of Section 4.13, intellectual
property matters, which are the subject of Section 4.14, or environmental laws, which are the subject of Section 4.15. 

4.10.    Tax Matters. The Company and its subsidiaries have timely prepared and filed all material tax returns
required to have been filed by them with all appropriate governmental agencies and timely paid all material taxes shown thereon or otherwise owed by them. There are no material unpaid assessments against the Company nor, to the Company’s
Knowledge, any audits by any federal, state or local taxing authority. All material taxes that the Company is required to withhold or to collect for payment have been duly withheld and collected and paid to the proper governmental entity or
third party when due. There are no tax liens pending or, to the Company’s Knowledge, threatened against the Company or any of its assets or property. With the exception of agreements or other arrangements that are not primarily
related to taxes entered into in the ordinary course of business, there are no outstanding tax sharing agreements or other such arrangements between the Company and any other corporation or entity (other than a subsidiary of the Company). 

  
 8 












 4.11.    Title to Properties. The Company and its subsidiaries
have good and marketable title to all real properties and all other tangible properties and assets owned by them, in each case free from liens, encumbrances and defects, except such as would not reasonably be expected, individually or in the
aggregate, to have a Material Adverse Effect; and the Company and its subsidiaries hold any leased real or personal property under valid and enforceable leases with no exceptions, except such as would not reasonably be expected, individually or in
the aggregate, to have a Material Adverse Effect. 
 4.12.    Certificates, Authorities and Permits. The Company
and its subsidiaries possess adequate certificates, authorities or permits issued by appropriate governmental agencies or bodies necessary to conduct the business now operated by them, except where failure to so possess would not reasonably be
expected, individually or in the aggregate, to result in a Material Adverse Effect. Neither the Company nor its subsidiaries have received any written notice of proceedings relating to the revocation or modification of any such certificate,
authority or permit that would reasonably be expected to have a Material Adverse Effect, individually or in the aggregate, on the Company or its subsidiaries, taken together. 

4.13.    Labor Matters. 

(a)        The Company is not party to or bound by any collective bargaining agreements or other
agreements with labor organizations. To the Company’s Knowledge, the Company has not violated in any material respect any laws, regulations, orders or contract terms affecting the collective bargaining rights of employees or labor
organizations, or any laws, regulations or orders affecting employment discrimination, equal opportunity employment, or employees’ health, safety, welfare, wages and hours. 

(b)        No material labor dispute with the employees of the Company, or with the employees of any
principal supplier, manufacturer, customer or contractor of the Company, exists or, to the Company’s Knowledge, is threatened or imminent. 

4.14.    Intellectual Property. The Company and its subsidiaries own, possess, license or have other rights to use,
all patents, patent applications, trade and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology, know-how and other intellectual
property (collectively, the “Intellectual Property”) necessary for the conduct of the Company’s business in all material respects as now conducted or as proposed in the SEC Filings to be conducted; and (a) except as
described in the SEC Filings, there are no rights of third parties to any such Intellectual Property, including no liens, security interests or other encumbrances; (b) to the Company’s Knowledge, there is no material infringement by third
parties of any such Intellectual Property; (c) there is no pending or, to the Company’s Knowledge, threatened action, suit, proceeding or claim by others challenging the Company’s rights in or to any such Intellectual Property;
(d) such Intellectual Property that is described in the SEC Filings has not been adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part; (e) there is no pending or, to the Company’s Knowledge,
threatened action, suit, proceeding or claim by others challenging the validity or scope of any such Intellectual Property that is owned or licensed by the Company, including interferences, oppositions, reexaminations or government proceedings;
(f) there is no pending or, to the Company’s Knowledge, threatened action, suit, proceeding or claim by others that the Company 

  
 9 












 
infringes, misappropriates, or otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights of others; and (g) to the Company’s Knowledge, each Company
employee involved with the development of Intellectual Property has entered into an invention assignment agreement with the Company. 

4.15.    Environmental Matters. The Company is not in violation of any statute, rule, regulation, decision or order
of any governmental agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances or relating to the protection or restoration of the environment or human exposure to hazardous or toxic
substances (collectively, “Environmental Laws”), has not released any hazardous substances regulated by Environmental Law onto any real property that it owns or operates and has not received any written notice or claim it is liable
for any off-site disposal or contamination pursuant to any Environmental Laws, which violation, release, notice, claim, or liability would reasonably be expected, individually or in the aggregate, to have a
Material Adverse Effect, and to the Company’s Knowledge, there is no pending or threatened investigation that would reasonably be expected to lead to such a claim. 

4.16.    Legal Proceedings. There are no legal, governmental or regulatory investigations, actions, suits or
proceedings pending to which the Company or its subsidiaries are or may reasonably be expected to become a party or to which any property of the Company or its subsidiaries are or may reasonably be expected to become the subject that, individually
or in the aggregate, would reasonably be expected to have a Material Adverse Effect. 
 4.17.    Financial
Statements. The financial statements included in each SEC Filing comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the
extent corrected by a subsequent restatement) and present fairly, in all material respects, the consolidated financial position of the Company as of the dates shown and its consolidated results of operations and cash flows for the periods shown,
subject in the case of unaudited financial statements to normal, immaterial year-end audit adjustments, and such consolidated financial statements have been prepared in conformity with United States generally
accepted accounting principles applied on a consistent basis during the periods involved (“GAAP”) (except as may be disclosed therein or in the notes thereto, and except that the unaudited financial statements may not contain all
footnotes required by GAAP, and, in the case of quarterly financial statements, except as permitted by Form 10-Q under the 1934 Act). Except as set forth in the financial statements of the Company included in
the SEC Filings filed prior to the date hereof, the Company has not incurred any liabilities, contingent or otherwise, except those incurred in the ordinary course of business, consistent (as to amount and nature) with past practices since the date
of such financial statements, none of which, individually or in the aggregate, have had or would reasonably be expected to have a Material Adverse Effect. 

4.18.    Insurance Coverage. The Company maintains in full force and effect insurance coverage that is customary
for comparably situated companies for the business being conducted and properties owned or leased by the Company, and the Company reasonably believes such insurance coverage to be adequate against all liabilities, claims and risks against which it
is customary for comparably situated companies to insure. 

  
 10 












 4.19.    Compliance with Nasdaq Continued Listing Requirements.
The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq
and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq. 

4.20.    Brokers and Finders. Other than the Placement Agents, no Person will have, as a result of the transactions
contemplated by the Transaction Documents, any valid right, interest or claim against or upon the Company or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on
behalf of the Company. No Investor shall have any obligation with respect to any fees, or with respect to any claims made by or on behalf of other Persons for fees, in each case of the type contemplated by this Section 4.20 that may be due in
connection with the transactions contemplated by this Agreement or the other Transaction Documents. 
 4.21.    No
Directed Selling Efforts or General Solicitation. Neither the Company nor any Person acting on its behalf has conducted any general solicitation or general advertising (as those terms are used in Regulation D) in connection with the offer
or sale of any of the Placement Securities. 
 4.22.    No Integrated Offering. Neither the Company nor its
subsidiaries nor any Person acting on their behalf has, directly or indirectly, made any offers or sales of any Company security or solicited any offers to buy any Company security, under circumstances that would adversely affect reliance by the
Company on Section 4(a)(2) and Regulation D for the exemption from registration for the transactions contemplated hereby or would require registration of the Placement Securities under the 1933 Act. 

4.23.    Private Placement. Assuming the accuracy of the representations and warranties of the Investors set forth
in Section 5, the offer and sale of the Placement Securities to the Investors and the exercise of the Warrants as contemplated hereby is exempt from the registration requirements of the 1933 Act. The issuance and sale of the Placement
Securities and the exercise of the Warrants do not contravene the rules and regulations of Nasdaq. 

4.24.    Questionable Payments. Neither the Company nor its subsidiaries nor, to the Company’s Knowledge, any
of their current or former directors, officers, employees, agents or other Persons acting on behalf of the Company or its subsidiaries, has on behalf of the Company or its subsidiaries in connection with their business: (a) used any corporate
funds for unlawful contributions, gifts, entertainment or other unlawful expenses relating to political activity; (b) made any direct or indirect unlawful payments to any governmental officials or employees from corporate funds;
(c) established or maintained any unlawful or unrecorded fund of corporate monies or other assets which is in violation of law; (d) made any false or fictitious entries on the books and records of the Company; (e) made any unlawful
bribe, rebate, payoff, influence payment, kickback or other unlawful payment of any nature or (f) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended. 

  
 11 












 4.25.    Office of Foreign Assets Control. Neither the Company
nor its subsidiaries nor, to the Company’s Knowledge, any of the current or former directors, officers, employees, agents or other Persons acting on behalf of the Company or its subsidiaries is currently the target of any U.S. sanctions
administered by the Office of Foreign Assets Control (“OFAC”) of the U.S. Treasury Department. The Company will not directly or indirectly use the proceeds of the offering of the Placement Securities contemplated hereby, or lend,
contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity for the purpose of financing the activities of any person that is the target of sanctions administered or enforced by such
authorities or in connection with any country or territory that is the target of country- or territory-wide OFAC sanctions (currently, the so-called Donetsk People’s Republic, Iran, the so-called Luhansk People’s Republic, Syria, Cuba, North Korea, and the Crimea Region of Ukraine). 

4.26.    Transactions with Affiliates. Except as disclosed in the SEC Filings, none of the executive officers or
directors of the Company and, to the Company’s Knowledge, none of the employees of the Company is presently a party to any transaction with the Company (other than as holders of stock options, warrants and/or restricted stock units, and for
services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise requiring payments
to or from any officer, director or such employee or, to the Company’s Knowledge, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner. 

4.27.    Internal Controls. The Company has established and maintains disclosure controls and procedures (as
defined in Rules 13a-15 and 15d-15 under the 1934 Act), which are designed to ensure that material information relating to the Company, including its subsidiaries, is
made known to the Company’s principal executive officer and its principal financial officer by others within those entities. Since the end of the Company’s most recent audited fiscal year, there have been no material weaknesses in the
Company’s internal control over financial reporting (whether or not remediated) and no change in the Company’s internal control over financial reporting that has materially affected, or would reasonably be expected to materially affect,
the Company’s internal control over financial reporting. The Company is not aware of any change in its internal controls over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or would
reasonably be expected to materially affect, the Company’s internal control over financial reporting. 

4.28.    Disclosures. Neither the Company nor any Person acting on its behalf has provided the Investors or their
agents or counsel with any information that constitutes or would reasonably be expected to constitute material non-public information concerning the Company or its subsidiaries, other than (A) with
respect to the transactions contemplated hereby, which will be disclosed in the Press Release (as defined below) and (B) if applicable to the Investor, the Additional Disclosure. The SEC Filings do not contain any untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements contained therein, in light of the circumstances under which they were made, not misleading. The Company understands and confirms that the Investors will rely on the
foregoing representations in effecting transactions in securities of the Company.

  
 12 












 4.29.    Required Filings. Except for the transactions
contemplated by this Agreement, including the acquisition of the Placement Securities contemplated hereby, no event or circumstance has occurred or information exists with respect to the Company or its business, properties, operations or financial
condition, which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so publicly announced or disclosed (assuming for this purpose that the SEC Filings are being incorporated by
reference into an effective registration statement filed by the Company under the 1933 Act). 
 4.30.    Investment
Company. The Company is not required to be registered as, and immediately following the Closing will not be required to register as, an “investment company” within the meaning of the Investment Company Act of 1940, as amended. 

4.31.    Tests and Preclinical and Clinical Trials. The studies, tests and preclinical and clinical trials that
were conducted, or are being conducted, by or on behalf of the Company and that are described in the SEC Filings were and, if still pending, are being, conducted (in the case of those conducted on behalf of the Company, to the Company’s
knowledge), in all material respects in accordance with the protocols submitted to the U.S. Food and Drug Administration (the “FDA”) or any foreign governmental body exercising comparable authority, procedures and controls pursuant to,
where applicable, accepted professional and scientific standards, and all applicable laws and regulations; the descriptions of the studies, tests and preclinical and clinical trials conducted by or, to the Company’s knowledge, on behalf of the
Company, and the results thereof, contained in the SEC Filings are accurate and complete in all material respects; the Company is not aware of any other studies, tests or preclinical and clinical trials, the results of which call into question, in
any material respect, the results described in SEC Filings; and the Company has not received any notices or correspondence from the FDA, any foreign, state or local governmental body exercising comparable authority or any Institutional Review Board
requiring the termination, suspension, material modification or clinical hold of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company that are material to the Company or that are related to any material
product candidate of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials. 

4.32.    Manipulation of Price. Neither the Company nor any of its subsidiaries has taken, and, to the
Company’s Knowledge, no Person acting on its behalf has taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale
of any of the Securities. 
 4.33.    Anti-Bribery and Anti-Money Laundering Laws. Each of the Company, its
subsidiaries and any of their respective officers, directors, supervisors, managers, agents, or employees are and have at all times been in compliance with and its participation in the offering will not violate: (A) anti-bribery laws, including
but not limited to, any applicable law, rule, or regulation of any locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of Foreign Public Officials in International
Business Transactions, signed December 17, 1997, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or regulation of similar purposes and scope or (B) anti-money
laundering laws, including, but not limited to, applicable federal, state, international, foreign or other laws, regulations or 

  
 13 












 
government guidance regarding anti-money laundering, including, without limitation, Title 18 US. Code sections 1956 and 1957, the Patriot Act, the Bank Secrecy Act, and international anti-money
laundering principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering, of which the United States is a member and with which designation the United States representative to the
group or organization continues to concur, all as amended, and any Executive order, directive, or regulation pursuant to the authority of any of the foregoing, or any orders or licenses issued thereunder. The Company will not directly or indirectly
use the proceeds of the offering of the Securities contemplated hereby, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity in violation of any anti-corruption,
anti-bribery, or anti-money laundering laws. 
 4.34.    No Bad Actors. No “bad actor” disqualifying
event described in Rule 506(d)(1)(i)-(viii) of the 1933 Act (a “Disqualification Event”) is applicable to the Company or, to the Company’s Knowledge, any Company Covered Person, except (i) for a Disqualification Event as
to which Rule 506(d)(2)(ii–iv) or (d)(3) is applicable and (ii) no such representation is made with respect to the Placement Agents, or any of their respective general partners, managing members, directors, executive officers or other
officers. 
 4.35.    No Additional Agreements. The Company has no other agreements or understandings (including,
without limitation, side letters) with any Investor to purchase Placement Securities on terms more favorable to such Investor than as set forth herein. 

4.36.    Shell Company Status. The Company is not, and has never been, an issuer identified in Rule 144(i)(1). 

4.37.    Compliance. The Company is not (i) in default under or in violation of (and no event has occurred
that has not been waived that, with notice or lapse of time or both, would result in a default by the Company under), nor has the Company received notice of a claim that it is in default under or that it is in violation of, any indenture, loan or
credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived) or (ii) in violation of any judgment, decree or order of
any court, arbitrator or governmental body, except in each case as could not have or reasonably be expected to result in a Material Adverse Effect. 

5.    Representations and Warranties of the Investors. Each of the Investors hereby severally, and not jointly,
represents and warrants to the Company that: 
 5.1.    Organization and Existence. Such Investor is a duly
incorporated or organized and validly existing corporation, limited partnership, limited liability company or other legal entity; has all requisite corporate, partnership or limited liability company power and authority to enter into and consummate
the transactions contemplated by the Transaction Documents and to carry out its obligations hereunder and thereunder, and to invest in the Securities pursuant to this Agreement; and is in good standing under the laws of the jurisdiction of its
incorporation or organization. 

  
 14 












 5.2.    Authorization. The execution, delivery and performance by
such Investor of the Transaction Documents to which such Investor is a party have been duly authorized and each has been duly executed and when delivered will constitute the valid and legally binding obligation of such Investor, enforceable against
such Investor in accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors’ rights generally, and
general principles of equity. 
 5.3.    Purchase Entirely for Own Account. The Securities to be received by such
Investor hereunder will be acquired for such Investor’s own account, not as nominee or agent, for the purpose of investment and not with a view to the resale or distribution of any part thereof in violation of the 1933 Act, and such Investor
has no present intention of selling, granting any participation in, or otherwise distributing the same in violation of the 1933 Act without prejudice, however, to such Investor’s right at all times to sell or otherwise dispose of all or any
part of such Securities in compliance with applicable federal and state securities laws. The Placement Securities are being purchased by such Investor in the ordinary course of its business. Nothing contained herein shall be deemed a representation
or warranty by such Investor to hold the Securities for any period of time. Such Investor is not a broker-dealer registered with the SEC under the 1934 Act or an entity engaged in a business that would require it to be so registered. 

5.4.    Investment Experience. Such Investor acknowledges that it can bear the economic risk and complete loss of
its investment in the Securities and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment contemplated hereby. 

5.5.    Disclosure of Information. Such Investor has had an opportunity to receive, review and understand all
information related to the Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms and conditions of the offering of the Securities, and has conducted and completed its
own independent due diligence. Such Investor acknowledges that copies of the SEC Filings are available on the EDGAR system. Based on the information described in the preceding sentence, representations and warranties of the Company contained in
Section 4 hereof and the information, including the information contained in the Transaction Documents, such Investor has deemed appropriate, and without reliance upon the Placement Agents, such Investor has independently made its own analysis
and decision to enter into the Transaction Documents. Such Investor is relying exclusively on its own investment analysis and due diligence (including professional advice it deems appropriate) with respect to the execution, delivery and performance
of the Transaction Documents, the Securities and the business, condition (financial and otherwise), management, operations, properties and prospects of the Company, including but not limited to all business, legal, regulatory, accounting, credit and
tax matters. Such Investor has not relied on any advice furnished by or on behalf of the Placement Agents in connection with the transactions contemplated hereby. Neither such inquiries nor any other due diligence investigation conducted by such
Investor shall modify, limit or otherwise affect such Investor’s right to rely on the Company’s representations and warranties contained in this Agreement. 

  
 15 












 5.6.    Restricted Securities. Such Investor understands that the
Placement Securities are characterized as “restricted securities” under the U.S. federal securities laws inasmuch as they are being acquired from the Company in a transaction not involving a public offering and that under such laws and
applicable regulations such Placement Securities may be resold without registration under the 1933 Act only in certain limited circumstances. 

5.7.    Legends. It is understood that, except as provided below, certificates or book-entry records evidencing the
Placement Securities may bear the following or any similar legend: 
 (a)        “The
securities represented hereby [and the securities issuable upon exercise of these securities] have not been registered with the Securities and Exchange Commission or the securities commission of any state in reliance upon an exemption from
registration under the Securities Act of 1933, as amended, and, accordingly, may not be transferred unless (i) such securities have been registered for sale pursuant to the Securities Act of 1933, as amended, (ii) such securities may be
sold pursuant to Rule 144, (iii) the Company has received an opinion of counsel reasonably satisfactory to it that such transfer may lawfully be made without registration under the Securities Act of 1933, as amended, or (iv) the
securities are transferred without consideration to an affiliate of such holder or a custodial nominee (which for the avoidance of doubt shall require neither consent nor the delivery of an opinion).” 

(b)        If required by the authorities of any state in connection with the issuance or sale of the
Placement Securities, the legend required by such state authority. 
 5.8.    Accredited Investor. Such Investor
is either (a) qualified institutional buyer as defined in Rule 144A of the 1933 Act or (b) an “accredited investor” within the meaning of Rule 501(a) of Regulation D. Such investor is a sophisticated institutional investor with
sufficient knowledge and experience in investing in private placement securities to properly evaluate the risks and merits of its purchase of the Placement Securities. Such Investor has determined based on its own independent review and such
professional advice as it deems appropriate that its purchase of the Placement Securities and participation in the transactions contemplated by the Transaction Documents (i) have been duly authorized and approved by all necessary action,
(ii) do not and will not violate or constitute a default under such Investor’s charter, bylaws or other constituent document or under any law, rule, regulation, agreement or other obligation by which such Investor is bound and
(iii) are a fit, proper and suitable investment for such Investor, notwithstanding the substantial risks inherent in investing in or holding the Placement Securities. 

5.9.    Placement Agents. Such Investor hereby acknowledges and agrees that it has independently evaluated the
merits of its decisions to purchase the Placement Securities and that (a) the Placement Agents are acting solely as placement agents in connection with the execution, delivery and performance of the Transaction Documents and are not acting as
an underwriters or in any other capacity and are not and shall not be construed as a fiduciary for such Investor, the Company or any other person or entity in connection with the execution, delivery and performance of the Transaction Documents,
(b) the Placement Agents have not made and will not make any representation or warranty, whether express or implied, of any kind or character, and have not provided any advice or recommendation in connection with the


  
 16 












 
execution, delivery and performance of the Transaction Documents, (c) neither of the Placement Agents will have any responsibility with respect to (i) any representations, warranties or
agreements made by any person or entity under or in connection with the execution, delivery and performance of the Transaction Documents, or the execution, legality, validity or enforceability (with respect to any person) thereof, or (ii) the
business, affairs, financial condition, operations, properties or prospects of, or any other matter concerning the Company, and (d) the Placement Agents will not have any liability or obligation (including without limitation, for or with
respect to any losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses or disbursements incurred by such Investor, the Company or any other person or entity), whether in contract, tort or otherwise, to such
Investor, or to any person claiming through it, in respect of the execution, delivery and performance of the Transaction Documents. 

5.10.    No General Solicitation. Such Investor did not learn of the investment in the Placement Securities as a
result of any general solicitation or general advertising. 
 5.11.    Brokers and Finders. No Person will have,
as a result of the transactions contemplated by the Transaction Documents, any valid right, interest or claim against or upon the Company or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or
understanding entered into by or on behalf of such Investor. 
 5.12.    Short Sales and Confidentiality Prior to the
Date Hereof. Other than consummating the transactions contemplated hereunder, such Investor has not, nor has any Person acting on behalf of or pursuant to any understanding with such Investor, directly or indirectly executed any purchases or
sales, including Short Sales, of the securities of the Company during the period commencing as of the time that such Investor was first contacted by the Company, the Placement Agents or any other Person regarding the transactions contemplated
hereby and ending immediately prior to the date hereof. Notwithstanding the foregoing, in the case of an Investor that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Investor’s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Investor’s assets, the representation set forth above shall only apply with respect to the
portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement and other than to such Person’s outside
attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the performance of the necessary or required tax, accounting, financial, legal, or administrative tasks and services and
other than as may be required by law, such Investor has maintained the confidentiality of all disclosures made to it in connection with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for
avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales
or similar transactions in the future. 
 5.13.    No Government Recommendation or Approval. Such Investor
understands that no United States federal or state agency, or similar agency of any other country, has reviewed, approved, passed upon, or made any recommendation or endorsement of the Company or the purchase of the Securities. 

  
 17 












 5.14.    No Intent to Effect a Change of Control. Such Investor
has no present intent to effect a “change of control” of the Company as such term is understood under the rules promulgated pursuant to Section 13(d) of the 1934 Act. 

5.15.    Residency. Such Investor’s office in which it has its principal place of business is located at the
address immediately below such Investor’s name on its signature page hereto. 
 5.16.    No Conflicts. The
execution, delivery and performance by such Investor of the Transaction Documents and the consummation by such Investor of the transactions contemplated hereby and thereby will not (i) result in a violation of the organizational documents of
such Investor or (ii) conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or cancellation of, any
agreement, indenture or instrument to which such Investor is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Investor, except in
the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Investor to perform
its obligations hereunder. 
 6.    Conditions to Closing. 

6.1.    Conditions to the Investors’ Obligations. The obligation of each Investor to purchase Placement
Securities at the Closing is subject to the fulfillment to such Investor’s satisfaction, on or prior to the Closing Date, of the following conditions, any of which may be waived by such Investor (as to itself only): 

(a)        The representations and warranties made by the Company in Section 4 hereof shall be
true and correct in all material respects, except for those representation and warranties qualified by materiality or Material Adverse Effect, which shall be true and correct in all respects, as of the date hereof and as of the Closing Date, as
though made on and as of such date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier
date. The Company shall have performed in all material respects all obligations and covenants herein required to be performed by it on or prior to the Closing Date. 

(b)        The Company shall have obtained any and all consents, permits, approvals, registrations and
waivers necessary for the consummation of the purchase and sale of the Placement Securities and the consummation of the other transactions contemplated by the Transaction Documents, all of which shall be in full force and effect. 

(c)        The Company shall have executed and delivered the Registration Rights Agreement. 

(d)        The Company shall have filed with Nasdaq a Notification Form: Listing of Additional Shares
for the listing of the Shares and the Warrant Shares. 

  
 18 












 (e)        No judgment, writ, order, injunction,
award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any
governmental authority, enjoining or preventing the consummation of the transactions contemplated hereby or in the other Transaction Documents. 

(f)        The Company shall have delivered a Certificate, executed on behalf of the Company by its
Chief Executive Officer or its Chief Financial Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in subsections (a), (b), (d), (e) and (j) of this Section 6.1. 

(g)        The Company shall have delivered a Certificate, executed on behalf of the Company by its
Secretary, dated as of the Closing Date, certifying the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by this Agreement, the other Transaction Documents and the issuance of the Placement
Securities, certifying the current versions of the Certificate of Incorporation and Bylaws of the Company and certifying as to the signatures and authority of persons signing the Transaction Documents and related documents on behalf of the Company.

 (h)        The Investors shall have received an opinion from Wilmer Cutler Pickering Hale and
Dorr LLP, the Company’s counsel, dated as of the Closing Date, in form and substance reasonably acceptable to the Investors. 

(i)        There shall have been no Material Adverse Effect with respect to the Company since the date
hereof. 
 (j)        No stop order or suspension of trading shall have been imposed by Nasdaq, the
SEC or any other governmental or regulatory body with respect to public trading in the Common Stock. 

6.2.    Conditions to Obligations of the Company. The Company’s obligation to sell and issue the Placement
Securities at the Closing as to any Investor is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which may be waived by the Company: 

(a)        The representations and warranties made by the Investors in Section 5 hereof shall be
true and correct in all material respects, except for those representations and warranties qualified by materiality or material adverse effect, which shall be true and correct in all respects, as of the date hereof, and shall be true and correct as
of the Closing Date with the same force and effect as if they had been made on and as of such date. The Investors shall have performed in all material respects all obligations and covenants herein required to be performed by them on or prior to the
Closing Date. 
 (b)        Each Investor shall have executed and delivered the Registration Rights
Agreement. 
 (c)        Any Investor purchasing Placement Securities at the Closing shall have paid
in full its purchase price to the Company. 

  
 19 












 6.3.    Termination of Obligations to Effect Closing; Effects.

 (a)        The obligations of the Company, on the one hand, and the Investors, on the other hand,
to effect the Closing shall terminate as follows: 
 (i)      Upon the mutual written consent of the Company
and Investors that agreed to purchase a majority of the Placement Securities to be issued and sold pursuant to this Agreement; 

(ii)      By the Company if any of the conditions set forth in Section 6.2 shall have become incapable of
fulfillment with respect to Investors that agreed to purchase a majority of the Placement Securities to be issued and sold pursuant to this Agreement, and shall not have been waived by the Company; 

(iii)      By an Investor (with respect to itself only) if any of the conditions set forth in Section 6.1
shall have become incapable of fulfillment, and shall not have been waived by such Investor; or 

(iv)      By either the Company or any Investor (with respect to itself only) if the Closing has not occurred
on or prior to the fifth Trading Day following the date of this Agreement; 
 provided, however, that, except in the case of clause (i) above, the
party seeking to terminate its obligation to effect the Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in this Agreement or the other Transaction Documents if such breach has resulted
in the circumstances giving rise to such party’s seeking to terminate its obligation to effect the Closing. 

(b)        In the event of termination by the Company or any Investor of its obligations to effect the
Closing pursuant to this Section 6.3, written notice thereof shall be given to the other Investors by the Company and the other Investors shall have the right to terminate their obligations to effect the Closing upon written notice to the
Company and the other Investors. Nothing in this Section 6.3 shall be deemed to release any party from any liability for any breach by such party of the terms and provisions of this Agreement or the other Transaction Documents or to impair the
right of any party to compel specific performance by any other party of its obligations under this Agreement or the other Transaction Documents. 

7.    Covenants and Agreements of the Company. 

7.1.    Nasdaq Listing. The Company will use commercially reasonable efforts to continue the listing and trading of
its Common Stock on Nasdaq and, in accordance therewith, will use commercially reasonable efforts to comply in all material respects with the Company’s reporting, filing and other obligations under the bylaws or rules of such market or
exchange, as applicable. 

  
 20 












 7.2.    Removal of Legends. 

(a)        In connection with any sale, assignment, transfer or other disposition of the Shares or
Warrant Shares by an Investor pursuant to Rule 144, pursuant to any other exemption under the 1933 Act or pursuant to a sale under an effective registration statement such that the purchaser acquires freely tradable shares and upon compliance
by the Investor with the requirements of this Agreement, if requested by the Investor, the Company shall request the transfer agent for the Common Stock (the “Transfer Agent”) to remove any restrictive legends related to the book
entry account holding such Shares or Warrant Shares and make a new, unlegended entry for such book entry shares sold or disposed of without restrictive legends within two (2) Trading Days of any such request therefor from such Investor,
provided that the Company has timely received from the Investor customary representations and other documentation reasonably acceptable to the Company in connection therewith. 

(b)        Subject to receipt from the Investor by the Company and the Transfer Agent of customary
representations and other documentation reasonably acceptable to the Company and the Transfer Agent in connection therewith, upon the earliest of such time as the Shares or Warrant Shares (i) have been registered for resale under the 1933 Act
pursuant to an effective registration statement, (ii) have been sold or transferred pursuant to an effective registration statement, (iii) have been sold pursuant to Rule 144, or (iv) are eligible for resale under Rule 144(b)(1)
or any successor provision (such earliest date, the “Effective Date”), the Company shall, in accordance with the provisions of this Section 7.2(b) and within two (2) Trading Days of any request therefor from an Investor
accompanied by such customary and reasonably acceptable documentation referred to above, (A) deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall make a new, unlegended entry for such book entry Shares or Warrant
Shares, and (B) use reasonable best efforts to cause its counsel to deliver to the Transfer Agent one or more opinions to the effect that the removal of such legends in such circumstances may be effected under the 1933 Act if required by the
Transfer Agent to effect the removal of the legend in accordance with the provisions of this Agreement. Shares or Warrant Shares subject to legend removal hereunder may be transmitted by the Transfer Agent to the Investor by crediting the account of
the Investor’s prime broker with the Depository Trust Company’s (“DTC”) system as directed by such Investor. The Company shall be responsible for the fees of its Transfer Agent and all DTC fees associated with such
issuance. 
 (c)        Each Investor, severally and not jointly with the other Investors, agrees
with the Company (i) that such Investor will sell any Securities only pursuant to either the registration requirements of the 1933 Act, including any applicable prospectus delivery requirements, or an exemption therefrom, (ii) that if
Shares or Warrant Shares are sold pursuant to a registration statement, they will be sold in compliance with the plan of distribution set forth therein and (iii) that if, after the effective date of the registration statement covering the
resale of the Shares and the Warrant Shares, such registration statement ceases to be effective and the Company has provided notice to such Investor to that effect, such Investor shall sell Shares and the Warrant Shares only in compliance with an
exemption from the registration requirements of the 1933 Act. 

  
 21 












 7.3.    Subsequent Equity Sales. 

(a)        From the date hereof until thirty (30) days after the Closing Date, without the consent
of the Required Investors, the Company shall not (A) issue shares of Common Stock or Common Stock Equivalents, (B) effect a reverse stock split, recapitalization, share consolidation, reclassification or similar transaction affecting the
outstanding Common Stock, or (C) file with the SEC a registration statement under the 1933 Act relating to any shares of Common Stock or Common Stock Equivalents, except pursuant to the terms of the Registration Rights Agreement and any other
agreements to which the Company is currently a party. Notwithstanding the foregoing, the provisions of this Section 7.3 shall not apply to (i) the issuance of the Securities hereunder, (ii) the issuance of Common Stock or Common Stock
Equivalents upon the conversion or exercise of any securities of the Company outstanding on the date hereof or outstanding pursuant to clause (iii) or (v) below, (iii) the issuance of any Common Stock or Common Stock Equivalents pursuant
to any Company stock-based compensation plans or in accordance with Nasdaq Stock Market Rule 5635(c)(4), (iv) the filing of a registration statement on Form S-8 under the 1933 Act to register the offer and
sale of securities on an equity incentive plan or employee stock purchase plan, (v) the issuance of Common Stock pursuant to the Open Market Sale AgreementSM between the Company and Jefferies
LLC, dated August 17, 2017, as amended or (vi) the issuance of any Common Stock or Common Stock Equivalents in connection with a transaction with an unaffiliated third party that includes a bona fide commercial relationship with the
Company (including any joint venture, marketing or distribution arrangement, strategic alliance, collaboration agreement or corporate partnering, intellectual property license agreement or acquisition agreement or other strategic transaction or debt
financing transaction with the Company); provided, however, that the aggregate number of shares of Common Stock issued pursuant to clause (v) or clause (vi) during the restricted period shall not exceed 10% of the total number of shares of
Common Stock issued and outstanding immediately following the Closing. 
 (b)        The Company
shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2 of the 1933
Act) that will be integrated with the offer or sale of the Placement Securities in a manner that would require the registration under the 1933 Act of the sale of the Placement Securities to the Investors, or that will be integrated with the offer or
sale of the Placement Securities for purposes of the rules and regulations of any trading market such that it would require stockholder approval prior to the closing of such other transaction unless stockholder approval is obtained before the
closing of such subsequent transaction. 
 7.4.    Fees. The Company shall be responsible for the payment of any
placement agent’s fees, financial advisory fees, or broker’s commissions (other than for Persons engaged by any Investor) relating to or arising out of the transactions contemplated hereby, including, without limitation, any fees or
commissions payable to the Placement Agents. 
 7.5.    Short Sales and Confidentiality After the Date Hereof.
Each Investor covenants that neither it nor any Affiliates acting on its behalf or pursuant to any understanding with it will trade in the securities of the Company or execute any Short Sales during the period from the date hereof until the earlier
of such time as (i) (a) the issuance of the Press Release or 

  
 22 












 
(b) if applicable to the Investor, the Additional Disclosure has been publicly disclosed by the Company or (ii) this Agreement is terminated in full. Notwithstanding the foregoing, in the
case of an Investor that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Investor’s assets and the portfolio managers have no direct knowledge of the investment decisions made by the
portfolio managers managing other portions of such Investor’s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the
Securities covered by this Agreement. Each Investor covenants that until such time (i) as issuance of the Press Release, such Investor and its Affiliates will maintain the confidentiality of the existence and terms of this Agreement and
(ii) if applicable to the Investor, the Additional Disclosure has been publicly disclosed by the Company, such Investor and its Affiliates will maintain the confidentiality of the Additional Disclosure, other than, in each case, to such
Person’s outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the performance of the necessary or required tax, accounting, financial, legal, or administrative
tasks and services and other than as may be required by law. 
 8.    Survival and Indemnification. 

8.1.    Survival. The representations, warranties, covenants and agreements contained in this Agreement shall
survive the Closing of the transactions contemplated by this Agreement for the applicable statute of limitations. 

8.2.    Indemnification. The Company agrees to indemnify and hold harmless each Investor and its Affiliates, and
their respective directors, officers, trustees, members, managers, employees, investment advisers and agents, from and against any and all losses, claims, damages, liabilities and expenses (including without limitation reasonable and documented
attorney fees and disbursements and other documented out-of-pocket expenses reasonably incurred in connection with investigating, preparing or defending any action,
claim or proceeding, pending or threatened and the costs of enforcement thereof) to which such Person may become subject as a result of any breach of representation, warranty, covenant or agreement made by or to be performed on the part of the
Company under the Transaction Documents, and will reimburse any such Person for all such amounts as they are incurred by such Person solely to the extent such amounts have been finally judicially determined not to have resulted from such
Person’s fraud or willful misconduct. 
 8.3.    Conduct of Indemnification Proceedings. Any
person entitled to indemnification hereunder shall (i) give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii) permit such indemnifying party to assume the defense of such
claim with counsel reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees
and expenses of such counsel shall be at the expense of such person unless (a) the indemnifying party has agreed in writing to pay such fees or expenses, (b) the indemnifying party shall have failed to assume the defense of such claim and
employ counsel reasonably satisfactory to such person or (c) in the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to
such claims (in 

  
 23 












 
which case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not
have the right to assume the defense of such claim on behalf of such person); and provided, further, that the failure of any indemnified party to give written notice as provided herein shall not relieve the indemnifying party of its
obligations hereunder, except to the extent that such failure to give notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in
connection with any proceeding in the same jurisdiction, be liable for fees or expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified
party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such
indemnified party of a release from all liability in respect of such claim or litigation. No indemnified party will, except with the consent of the indemnifying party, which consent shall not be unreasonably withheld, conditioned or delayed, consent
to entry of any judgment or enter into any settlement. 
 9.    Miscellaneous. 

9.1.    Successors and Assigns. This Agreement may not be assigned by a party hereto without the prior written
consent of the Company or each of the Investors, as applicable, provided, however, that an Investor may assign its rights and delegate its duties hereunder in whole or in part to an Affiliate or to a third party acquiring some or all of its
Securities in a transaction complying with applicable securities laws without the prior written consent of the Company or the other Investors, provided such assignee agrees in writing to be bound by the provisions hereof that apply to Investors. The
provisions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties. Without limiting the generality of the foregoing, in the event that the Company is a party to a merger,
consolidation, share exchange or similar business combination transaction in which the Common Stock is converted into the equity securities of another Person, from and after the effective time of such transaction, such Person shall, by virtue of
such transaction, be deemed to have assumed the obligations of the Company hereunder, the term “Company” shall be deemed to refer to such Person and the term “Securities” shall be deemed to refer to the securities received by the
Investors in connection with such transaction. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective permitted successors and assigns any rights, remedies, obligations,
or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

9.2.    Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an
original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via electronic mail (including pdf or any electronic signatures complying with the U.S. federal ESIGN Act of 2000 or the New York
Electronic Signatures and Records Act, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

  
 24 












 9.3.    Titles and Subtitles. The titles and subtitles used in
this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 

9.4.    Notices. Unless otherwise provided, any notice required or permitted under this Agreement shall be given in
writing and shall be deemed effectively given as hereinafter described (i) if given by personal delivery, then such notice shall be deemed given upon such delivery, (ii) if given by e-mail, then such
notice shall be deemed given upon receipt of confirmation of confirmation of receipt of an e-mail transmission, (iii) if given by mail, then such notice shall be deemed given upon the earlier of
(A) receipt of such notice by the recipient or (B) three days after such notice is deposited in first class mail, postage prepaid, and (iv) if given by an internationally recognized overnight air courier, then such notice shall be
deemed given one Business Day after delivery to such carrier. All notices shall be addressed to the party to be notified at the address as follows, or at such other address as such party may designate by ten days’ advance written notice to the
other party: 
 If to the Company: 

Karyopharm Therapeutics Inc. 

85 Wells Avenue 
 Newton,
Massachusetts 02459 
 Attention: Michael Mano 

E-mail: Michael.Mano@Karyopharm.com 

With a copy (which shall not constitute notice) to: 

Wilmer Cutler Pickering Hale and Dorr LLP 

60 State Street 
 Boston,
Massachusetts 02109 
 Attention: Jason Kropp 

Email: jason.kropp@wilmerhale.com 

If to the Investors: 
 Only to
the addresses set forth on the signature pages hereto. 
 9.5.    Expenses. The parties hereto shall pay their
own costs and expenses in connection herewith regardless of whether the transactions contemplated hereby are consummated; it being understood that each of the Company and each Investor has relied on the advice of its own respective counsel. 

9.6.    Amendments and Waivers. Prior to Closing, no amendment or waiver of any provision of this Agreement will be
effective with respect to any party unless made in writing and signed by a duly authorized representative of such party. Following the Closing, any term of this Agreement may be amended and the observance of any term of this Agreement may be waived
(either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Required Investors. Notwithstanding the 

  
 25 












 
foregoing, this Agreement may not be amended and the observance of any term of this Agreement may not be waived with respect to any Investor without the written consent of such Investor unless
such amendment or waiver applies to all Investors in the same fashion. Any amendment or waiver effected in accordance with this paragraph shall be binding upon (i) prior to Closing, each Investor that signed such amendment or waiver and
(ii) following the Closing, each holder of any Securities purchased under this Agreement at the time outstanding, and in each case, each future holder of all such Securities and the Company. 

9.7.    Publicity. 

(a)        Except as set forth below, no public release or announcement concerning the transactions
contemplated hereby shall be issued by the Investors without the prior consent of the Company, except as such release or announcement may be required by law or the applicable rules or regulations of any securities exchange or securities market, in
which case the Investors shall allow the Company reasonable time to comment on such release or announcement in advance of such issuance. Notwithstanding the foregoing, each Investor may identify the Company and the value of such Investor’s
security holdings in the Company in accordance with applicable investment reporting and disclosure regulations or internal policies without prior notice to or consent from the Company (including, for the avoidance of doubt, filings pursuant to
Sections 13 and 16 of the 1934 Act). The Company shall not include the name of any Investor or any Affiliate or investment adviser of such Investor in any press release or public announcement (which, for the avoidance of doubt, shall not include any
SEC Filing to the extent such disclosure is required by SEC rules and regulations) without the prior written consent of such Investor. 

(b)        No later than the Trading Day immediately following the date hereof, the Company shall
issue one or more press releases disclosing all material terms of the transactions contemplated by this Agreement (the “Press Releases”). From and after the issuance of the Press Release, any Investor who did not receive the
Additional Disclosure shall not be in possession of any material, non-public information received from the Company or any of its officers, directors, affiliates, employees or agents (including the Placement
Agents). 
 (c)        No later than 10 days after the date of this Agreement, the Company shall
issue a press release and/or a Current Report on Form 8-K disclosing the Additional Disclosure (the “Cleansing Disclosure”), as such material non-public
information may be updated from time-to-time including through the inclusion of additional data. From and after the issuance of the Cleansing Disclosure, no Investor who
received the Additional Disclosure shall be in possession of any material non-public information received from the Company, its subsidiaries or any of their respective officers, directors, employees or agents
(including the Placement Agents). 
 (d)        The Company understands and confirms that the
Investors will rely on the foregoing representations in effecting transactions in securities of the Company. The Company will make such other filings and notices in the manner and time required by the SEC or Nasdaq. 

  
 26 












 9.8.    Severability. Any provision of this Agreement that is
prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written
so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent
permitted by applicable law, the parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable in any respect. 

9.9.    Benefit of Agreement. The Placement Agents are an intended third-party beneficiary of the representations
and warranties of the Company and of each Investor set forth in Section 4 and Section 5, respectively, of this Agreement. 

9.10.    Entire Agreement. This Agreement, including the signature pages, Exhibits, the other Transaction Documents
and any confidentiality agreements between the Company and each Investor constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, both oral
and written, between the parties with respect to the subject matter hereof and thereof. 
 9.11.    Other
Agreements. The Company has not entered into any side letter or similar agreement with any Investor pursuant to which such Investor has been or will be granted any terms relating to the Placement Securities or the registration therefore that are
more favorable to such Investor than the terms granted to each other Investor.  
 9.12.    Further
Assurances. The parties shall execute and deliver all such further instruments and documents and take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the
agreements herein contained. 
 9.13.    Governing Law; Consent to Jurisdiction; Waiver of Jury Trial. This
Agreement shall be governed by, and construed in accordance with, the laws of the State of New York without regard to the choice of law principles thereof (other than sections 5-1401 and 5-1402 of the General Obligations of Law). Each of the parties hereto irrevocably submits to the exclusive jurisdiction of the courts of the State of New York located in New York County and the United States
District Court for the Southern District of New York for the purpose of any suits, action, proceeding or judgement relating to or arising out of this Agreement and the transactions contemplated hereby. Service of process in connection with any such
suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this Agreement. Each of the parties hereto irrevocably consents to the jurisdiction of any such
court in any such suit, action or proceeding to the laying of venue in such court. Each party hereto irrevocably waives any objection to the laying of venue of any such suit, action or proceeding brought in such courts and irrevocably waives any
claim that any such suit, action or proceeding brought in any such court has been brought in an inconvenient forum. To the extent that the Company has or hereafter may acquire any immunity (on the grounds of sovereignty or otherwise) from the
jurisdiction of any court or from any legal process with respect to itself or its property, the Company irrevocably waives, to the fullest extent permitted by law, such immunity in respect of any suit, action or proceeding. EACH OF THE PARTIES
HERETO WAIVES ANY RIGHT TO REQUEST A TRIAL BY JURY IN ANY LITIGATION WITH RESPECT TO THIS AGREEMENT AND REPRESENTS THAT COUNSEL HAS BEEN CONSULTED SPECIFICALLY AS TO THIS WAIVER. 

  
 27 












 9.14.    Independent Nature of Investors’ Obligations and
Rights. The obligations of each Investor under any Transaction Document are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations of any other
Investor under any Transaction Document. The decision of each Investor to purchase Placement Securities pursuant to the Transaction Documents has been made by such Investor independently of any other Investor. Nothing contained herein or in any
Transaction Document, and no action taken by any Investor pursuant thereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in
any way acting in concert or as a group (including a “group” within the meaning of Section 13(d)(3) of the 1934 Act) with respect to such obligations or the transactions contemplated by the Transaction Documents. Each Investor
acknowledges that no other Investor has acted as agent for such Investor in connection with making its investment hereunder and that no Investor will be acting as agent of such Investor in connection with monitoring its investment in the Securities
or enforcing its rights under the Transaction Documents. Each Investor shall be entitled to independently protect and enforce its rights, including, without limitation, the rights arising out of this Agreement or out of the other Transaction
Documents, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The Company acknowledges that each of the Investors has been provided with the same Transaction Documents for the
purpose of closing a transaction with multiple Investors and not because it was required or requested to do so by any Investor. It is expressly understood and agreed that each provision contained in this Agreement is between the Company and an
Investor, solely, and not between the Company and the Investors collectively and not between and among the Investors. 

9.15.    Exculpation of the Placement Agents. Each party hereto agrees for the express benefit of the Placements
Agent and its Affiliates and representatives that: 
 (a)        none of the
Placement Agents, their respective Affiliates or any of their representatives (1) has any duties or obligations other than those specifically set forth herein or (x) with respect to Jefferies LLC, in the engagement letter, dated as of
November 22, 2022, between the Company and Jefferies LLC and (y) with respect to Piper Sandler & Co., in the engagement letter, dated as of November 29, 2022, between the Company and Piper Sandler & Co., (C) with
respect to Barclays Capital, Inc., dated as of December 4, 2022 between the Company and Barclays Capital, Inc., (D) with respect to Robert W. Baird & Co. Incorporated, dated as of December 4, 2022 between the Company and Robert W. Baird &
Co. Incorporated and (E) with respect to H.C. Wainwright & Co., LLC, dated as of December 4, 2022 between the Company and H.C. Wainwright & Co., LLC; (2) shall be liable for any improper payment made in accordance with the information
provided by the Company; (3) makes any representation or warranty, or has any responsibilities as to the validity, accuracy, value or genuineness of any information, certificates or documentation delivered by or on behalf of the Company
pursuant to this Agreement or the Transaction Documents or in connection with any of the transactions contemplated hereby and thereby; or (4) shall be liable (x) for any action taken, suffered or omitted by any of them in good faith and
reasonably believed to be authorized or within the discretion or rights or powers conferred upon it by this Agreement or any Transaction Document or (y) for anything which any of them may do or refrain from doing in connection with this
Agreement or any Transaction Document, except in each case for such party’s own gross negligence, willful misconduct or bad faith. 

  
 28 












 (b)        The Placement Agents, their Affiliates
and their representatives shall be entitled to (1) rely on, and shall be protected in acting upon, any certificate, instrument, notice, letter or any other document or security delivered to any of them by or on behalf of the Company, and
(2) be indemnified by the Company for acting as the Placement Agents hereunder pursuant to the indemnification provisions set forth in the applicable engagement letter. 

[remainder of page intentionally left blank] 

  
 29 












 IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized
officers to execute this Agreement as of the date first above written. 
  

							
	COMPANY:	 		 	KARYOPHARM THERAPEUTICS INC.
				
		 		 	By:	 	 /s/ Michael Mason

		 		 	Name:	 	Michael Mason
		 		 	Title:	 	Chief Financial Officer












 INVESTOR: 

 

			
	By:	 	  

	Name:	 	
	Title:	 	













 EXHIBIT A 

Schedule of Investors 
  

													
	 Investor Name
	  	Number of Shares
to be Purchased	 	  	Number of Warrants
to be Purchased	 	  	Aggregate
Purchase Price	 
	 Avidity Partners
	  	 	9,633,911	 	  	 	2,890,173	 	  	$	49,999,998	 
	 Funds Affiliated with Rubric Capital Management LP
	  	 	3,853,565	 	  	 	1,156,069	 	  	$	20,000,002	 
	 Armistice Capital Master Fund Ltd.
	  	 	3,853,565	 	  	 	1,156,069	 	  	$	20,000,002	 
	 Citadel CEMF Investments Ltd.
	  	 	1,926,782	 	  	 	578,034	 	  	$	9,999,999	 
	 Iron Triangle Master Fund LP
	  	 	1,926,782	 	  	 	578,034	 	  	$	9,999,999	 
	 Woodline Master Fund LP
	  	 	1,926,782	 	  	 	578,034	 	  	$	9,999,999	 
	 Marshall Wace Investment Strategies – Eureka Fund
	  	 	1,926,782	 	  	 	578,034	 	  	$	9,999,999	 
	 Funds Affiliated with SilverArc Capital Management, LLC
	  	 	1,541,426	 	  	 	462,427	 	  	$	8,000,001	 
	 CVI Investments, Inc.
	  	 	1,252,408	 	  	 	375,722	 	  	$	6,499,998	 
	 Adage Capital Partners LP
	  	 	770,713	 	  	 	231,213	 	  	$	4,000,000	 
	 Point72 Associates, LLC
	  	 	770,713	 	  	 	231,213	 	  	$	4,000,000	 
	 Altium Growth Fund, LP
	  	 	674,374	 	  	 	202,312	 	  	$	3,500,001	 
	 HealthCor Therapeutics Master Fund, LP
	  	 	578,035	 	  	 	173,410	 	  	$	3,000,002	 
	 Funds Affiliated with Monashee Investment Management LLC
	  	 	481,696	 	  	 	1,44,608	 	  	$	2,500,002	 
	 Alyeska Master Fund, L.P.
	  	 	481,696	 	  	 	144,508	 	  	$	2,500,002	 
	 Funds Affiliated with DAFNA Lifescience LP
	  	 	192,678	 	  	 	57,803	 	  	$	999,999	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 
	 TOTAL
	  	 	31,791,908	 	  	 	9,537,563	 	  	$	165,000,003	 
		  	  
	  
	 	  	  
	  
	 	  	  
	  
	 


  
 32